<SEC-DOCUMENT>0001206774-13-003453.txt : 20131001
<SEC-HEADER>0001206774-13-003453.hdr.sgml : 20131001
<ACCEPTANCE-DATETIME>20131001093353
ACCESSION NUMBER:		0001206774-13-003453
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20131001
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131001
DATE AS OF CHANGE:		20131001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		131125351

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED STATES <BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549
<BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>SECURITIES EXCHANGE
ACT OF 1934</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of Earliest Event
Reported): </FONT><B><FONT face="Times New Roman" size=2>October 1, 2013</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></B><FONT face="Times New Roman" size=2> <BR></FONT><FONT face="Times New Roman" size=2>(Exact name of registrant
as specified in its charter) </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(State or other
jurisdiction</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(IRS Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>of incorporation)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>Identification
  No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE, SUITE
2070<BR>MENLO PARK, CALIFORNIA 94025<BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650) 473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant's telephone number, including area code)
</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A <BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since last report) </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction
A.2. below): </FONT></P>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>&#168;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Written communications pursuant
      to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>&#168;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to
      Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>&#168;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Pre-commencement communications
      pursuant to Rule 14d-2(b) under the Exchange Act (17 </FONT><FONT face="Times New Roman" size=2>CFR 240.14d-2(b))</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>&#168;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Pre-commencement communications
      pursuant to Rule 13e-4(c) under the Exchange Act (17 </FONT><FONT face="Times New Roman" size=2>CFR 240.13e-4(c))</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Item 2.01 Completion of Acquisition or
Disposition of Assets. </FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>On October
1, 2013, Geron Corporation (the &#147;Company&#148; or &#147;Geron&#148;) announced the closing of
the transaction to divest the Company&#146;s human embryonic stem cell assets
pursuant to the terms of the previously disclosed Asset Contribution Agreement,
dated as of January 4, 2013, by and amongst Geron, BioTime, Inc. (&#147;BioTime&#148;),
and BioTime&#146;s wholly owned subsidiary, Asterias Biotherapeutics, Inc. (formerly
known as BioTime Acquisition Corporation) (&#147;Asterias&#148;).</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Under the terms of the Asset
Contribution Agreement, on October 1, 2013, Geron contributed to Asterias
Geron&#146;s human embryonic stem cell assets, including intellectual property,
proprietary technology, materials, <FONT STYLE="BACKGROUND-COLOR: transparent">equipment, reagents</font>, contracts, regulatory
filings, Geron&#146;s Phase I clinical trial of oligodendrocyte progenitor cells in
patients with acute spinal cord injury, and Geron&#146;s autologous cellular
immunotherapy program, including data from the Phase I/II clinical trial of the
autologous immunotherapy in patients with acute myelogenous leukemia (together
with the Phase 1 clinical trial of oligodendrocyte progenitor cells in patients
with acute spinal cord injury, the &#147;Clinical Studies&#148;). On October 1, 2013,
Asterias assumed all post-closing liabilities with respect to all of the assets
contributed by Geron, including any liabilities related to the Clinical Studies.
Additionally, Asterias will be substituted for Geron as a party in an appeal by
Geron of two rulings in favor of ViaCyte, Inc. by the United States Patent and
Trademark Office&#146;s Board of Patent Appeals and Interferences, filed by Geron in
the United States District Court for the Northern District of California on
September 13, 2012 (the &#147;ViaCyte Appeal&#148;), and Asterias assumed all liabilities
arising after October 1, 2013 with respect to the ViaCyte Appeal. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As consideration for the
contribution of Geron&#146;s human embryonic stem cell assets to Asterias, on October
1, 2013, Asterias issued to Geron 6,537,779 shares of Asterias Series A common
stock. <FONT STYLE="BACKGROUND-COLOR: transparent">Asterias will also pay royalties to Geron on the sale of
products that are commercialized, if any, in reliance upon Geron patents
acquired by Asterias.</FONT> Under the terms of the Asset Contribution Agreement and subject to
applicable law, Geron will distribute all of the shares of Asterias Series A
common stock to Geron's stockholders on a pro rata basis (the &#147;Series A
Distribution&#148;), other than with respect to fractional shares and stockholders in
certain to-be-determined excluded jurisdictions, who will instead receive cash
on a pro rata basis. To initiate the Series A Distribution, Geron will set a
record date, following notice from BioTime and Asterias that certain securities
registration or qualification requirements have been met. Only Geron
stockholders as of that record date will be eligible to participate in the
Series A Distribution. Geron stockholders should note that Asterias is a newly
organized, development stage company in the start-up phase, and has not yet
commenced its primary product development programs. Although Asterias plans to
arrange for the trading of the Asterias Series A common stock on the OTC
Bulletin Board upon the completion of the Series A Distribution, there is no
existing public market for the Asterias Series A common stock, nor may one ever
develop. Geron stockholders are cautioned that any value that Geron stockholders
may ascribe to the Asterias Series A common stock or the related BioTime
Warrants is highly speculative. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On October 1, 2013, BioTime
contributed to Asterias 8,902,077 shares of BioTime common stock, five-year
warrants to purchase 8,000,000 additional shares of BioTime common stock at an
exercise price of $5.00 per share (the &#147;BioTime Warrants&#148;)<FONT STYLE="BACKGROUND-COLOR: transparent">, minority</FONT> stakes in two <FONT STYLE="BACKGROUND-COLOR: transparent">of</FONT> BioTime&#146;s subsidiaries, OrthoCyte Corporation and Cell
Cure Neurosciences, Ltd., and certain embryonic stem cell lines produced by
BioTime&#146;s subsidiary, ES Cell International Pte Ltd, together with a
non-exclusive license to Asterias to use such materials for any and all
purposes. <FONT STYLE="BACKGROUND-COLOR: transparent">In addition, BioTime had previously loaned Asterias $5 million in cash and the principal amount of this debt was cancelled as part of the closing.</FONT> In consideration <FONT STYLE="BACKGROUND-COLOR: transparent">of BioTime&#146;s contributions</FONT>, Asterias issued to BioTime 21,773,340 shares of
Asterias Series B common stock and three-year warrants
to purchase 3,150,000 additional shares of Asterias Series B common stock at an
exercise price of $5.00 per share. Upon completion of the Series A Distribution,
Asterias will distribute the BioTime Warrants on a pro rata basis to the holders
of Asterias Series A common stock.</FONT></P>


<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2><FONT STYLE="BACKGROUND-COLOR: transparent">Further information about the Series A Distribution and the BioTime Warrants distribution will be available upon the record date, which is expected to occur within the next 60 days. A public announcement regarding the record date is expected to occur at least ten days prior to the record date.</FONT></FONT></P>


<P align=center><FONT face="Times New Roman" size=2>2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>The
foregoing description of the Asset Contribution Agreement and the transactions
contemplated thereby does not purport to be complete and is qualified in its
entirety by reference to the Asset Contribution Agreement, a copy of which was
filed by the Company as Exhibit 2.1 to the Company&#146;s Current Report on Form 8-K
filed on January 8, 2013, and is incorporated herein by reference. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Item 9.01 Financial Statements and
Exhibits.</FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><B><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT></B></TD>
    <TD vAlign=top noWrap><STRONG><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD width="100%" colSpan=4><B><FONT face="Times New Roman" size=2>Exhibits.</FONT></B></TD></TR>
  <TR>
    <TD width="100%" colSpan=6>&nbsp;</TD></TR>
  <TR>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD noWrap><STRONG><FONT size=2 face="Times New Roman">&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap><B><FONT face="Times New Roman" size=2>Exhibit No. </FONT></B></TD>
    <TD noWrap><FONT size=2 face="Times New Roman"><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</STRONG></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap><STRONG><FONT size=2 face="Times New Roman">Description</FONT></STRONG></TD>
    <TD width="100%"><STRONG><FONT size=2 face="Times New Roman">&nbsp;</FONT></STRONG></TD></TR>
  <TR>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD noWrap><STRONG><FONT size=2 face="Times New Roman">&nbsp;</FONT></STRONG></TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center; background-color: Silver"><FONT size=2 face="Times New Roman">2.1</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; background-color: Silver"></TD>
    <TD COLSPAN="2" STYLE="width: 100%; background-color: Silver"><FONT face="Times New Roman" size=2>Asset Contribution
      Agreement by and among Geron Corporation, BioTime, Inc., and Asterias
      Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation)
      (incorporated herein by reference to Exhibit 2.1 in the Company&#146;s Current
      Report on Form 8-K (File No. 000-20859), as filed with the Securities and
      Exchange Commission on January 8, 2013)*</FONT></TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap>&nbsp;</TD>
    <TD vAlign=top width="100%" colSpan=3>____________________<BR>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Schedules have been omitted pursuant to Item 601(b)(2)
      of Regulation S-K. The Company undertakes to furnish supplemental copies
      of any of the omitted schedules upon request by the Securities and
      Exchange Commission.</FONT></TD></TR></TABLE>
<P align=left><B><FONT face="Times New Roman" size=2>Use of Forward-Looking
Statements</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Except for the historical information
contained herein, this Current Report on Form 8-K contains forward-looking
statements made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that
statements in this Current Report on Form 8-K regarding: (a) the value to Geron
stockholders of the <FONT STYLE="BACKGROUND-COLOR: transparent">Asterias</FONT> Series A <FONT STYLE="BACKGROUND-COLOR: transparent">common stock</FONT> and the BioTime Warrants; (b) Geron's
plans or expectations for or of the Series A Distribution and the BioTime
Warrants to be distributed as contemplated by the Asset Contribution Agreement,
and statements related thereto<FONT STYLE="BACKGROUND-COLOR: transparent">, including Geron&rsquo;s expectation for the timing of the record date and the announcement of the record date for the Series A Distribution</FONT>; (c) Geron receiving royalties on the sale of
products that are commercialized, if any; (d) Geron&#146;s payment of cash in lieu of
fractional and other shares; and (e) Asterias&#146; plans to arrange for the trading
of the Asterias Series A common stock on the OTC Bulletin Board, constitute
forward-looking statements. These statements involve risks and uncertainties
that can cause actual results to differ materially from those in such
forward-looking statements. These risks and uncertainties, include, without
limitation: (i) the possibility that Geron stockholders may realize little or no
value from the Asterias Series A common stock and/or the BioTime <FONT STYLE="BACKGROUND-COLOR: transparent">Warrants;</FONT> (ii) the potential inability of Geron to
complete the Series A Distribution or of Asterias to distribute the BioTime
Warrants, as well as the payment of cash in lieu of fractional and other shares,
in a timely manner or at all, including as a result of the failure of BioTime
and/or Asterias to obtain or maintain required federal and state registrations
and qualifications necessary to enable the Series A Distribution, the BioTime
Warrants distribution, and related transactions; (iii) the possibility of
litigation that could arise as a result of or in connection with the Series A
Distribution, the BioTime Warrants distribution and related transactions, as
well as the asset contribution transaction itself, including litigation arising
from the possibility that Geron stockholders may realize little or no value from
the Asterias Series A common stock and/or the BioTime <FONT STYLE="BACKGROUND-COLOR: transparent">Warrants;</FONT> and (iv) that there is no existing public market for either
the Asterias Series A common stock or the BioTime Warrants, nor may a public
market for such securities ever develop. Additional information and factors that
could cause actual results to differ materially from those in the
forward-looking statements are contained in Geron's periodic reports filed with
the Securities and Exchange Commission under the heading "Risk Factors,"
including Geron's quarterly report on Form 10-Q for the quarter ended June 30,
2013. Undue reliance should not be placed on forward-looking statements, which
speak only as of the date they are made, and the facts and assumptions
underlying the forward-looking statements may change. Except as required by law,
Geron disclaims any obligation to update these forward-looking statements to
reflect future information, events or circumstances. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Date: October 1, 2013</FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">By:</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="29%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;/s/
      Stephen N. Rosenfield</FONT></TD>
    <TD noWrap align=left width="20%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;Stephen N.
      Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;Executive Vice
      President, General</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;Counsel and
      Corporate Secretary</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>4</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>EXHIBIT</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>INDEX </FONT></B></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="2%"><B><FONT face="Times New Roman" size=2>Exhibit No.</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD>
    <TD noWrap align=left width="95%">&nbsp;</TD></TR>
  <TR STYLE="background-color: Silver">
    <TD vAlign=top noWrap align=center width="2%"><FONT face="Times New Roman" size=2>2.1</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="97%" colSpan=2><FONT face="Times New Roman" size=2>Asset Contribution
      Agreement by and among Geron Corporation, BioTime, Inc., and Asterias
      Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation)
      (incorporated herein by reference to Exhibit 2.1 in the Company&#146;s Current
      Report on Form 8-K (File No. 000-20859), as filed with the Securities and
      Exchange Commission on January 8, 2013)*</FONT></TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top width="100%" colSpan=2>____________________<BR>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Schedules have been omitted
      pursuant to Item 601(b)(2) of Regulation S-K. The Company undertakes to
      furnish supplemental copies of any of the omitted schedules upon request
      by the Securities and Exchange Commission.</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
